Barclay’s analysts took a close look at the Novo Nordisk share on Wednesday. That is the expert assessment.
The British investment bank Barclays has lowered the price target for Novo Nordisk from 900 to 700 Danish crowns, but left the classification to “Overweight”. Analyst Emily Field considers a recovery of the prescription figures for weight loss in the United States, according to a comment on Wednesday before the summer. The Danes were currently at the bottom of the target span for the overall year when it comes to growth in sales for the overall year.
On Wednesday, the Novo Nordisk share in Copenhagen finally showed 1.03 percent lower at 421.25 Danish crowns.
/AG/EDH
Publication of the original study: 04/15/2025 / 20:31 / GMT
First disclosure of the original study: 16.04.2025 / 03:00 / GMT
Note: Information on the obligation to disclose the disclosure for conflicts of interest within the meaning of Section 85 (1) WPHG, Art. 20 VO (EU) 596/2014 For the Analysten House mentioned can be found at http://web.dpa-afx.de/offengegungs-
London (dpa-AfX analyzer)
Selected leverage products on Novo Nordisk
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Novo Nordisk
The lever must be between 2 and 20
Advertising